Skip to main content
Journal for Immunotherapy of Cancer logoLink to Journal for Immunotherapy of Cancer
. 2022 Sep 12;10(9):e003960corr1. doi: 10.1136/jitc-2021-003960corr1

Correction: Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy

PMCID: PMC9472126  PMID: 36096540

Jiang X, Wang J, Zheng X, et al. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. J Immunother Cancer 2022;10:e003960. doi:10.1136/jitc-2021-003960

The author Jian Wang has had the following affiliation added: Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China


Articles from Journal for Immunotherapy of Cancer are provided here courtesy of BMJ Publishing Group

RESOURCES